Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Vetoquinol SA
  6. News
  7. MarketScreener Strategies
    VETO   FR0004186856

VETOQUINOL SA

(VETO)
  Report
Real-time Euronext Paris  -  12:35:25 2023-03-24 pm EDT
85.40 EUR   +7.15%
03/23Global markets live: Shell, UBS, Nvidia, Coinbase, Block...
MS
03/23Vetoquinol : Inside Information / News release on accounts, results
PU
03/23Vetoquinol SA Proposes Dividend
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vetoquinol SA : Helped by a technical support level

03/17/2023 | 02:26am EDT
long trade
Live
Entry price : 81.4€ | Target : 94€ | Stop-loss : 75€ | Potential : 15.48%
The medium term support area around 77.4 EUR should allow Vetoquinol SA shares to re-establish an upward trend in the short term.
Investors have an opportunity to buy the stock and target the € 94.
Vetoquinol SA : Vetoquinol SA : Helped by a technical support level
Strengths
  • The company is in a robust financial situation considering its net cash and margin position.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses
  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart
Subsector Veterinary Drugs
1st jan.Capitalization (M$)Investor Rating
VETOQUINOL SA-2.51%1 087
ZOETIS12.03%76 006
ELANCO ANIMAL HEALTH INCORP..-27.82%4 335
DECHRA PHARMACEUTICALS PLC-2.60%3 549
BLUESTAR ADISSEO COMPANY7.63%3 472
VIRBAC27.41%2 641
CHINA ANIMAL HUSBANDRY INDU..20.83%2 088
WUHAN KEQIAN BIOLOGY CO.,LT..16.70%1 775
JINYU BIO-TECHNOLOGY CO., L..18.76%1 703
PULIKE BIOLOGICAL ENGINEERI..3.84%1 432
TIANJIN RINGPU BIO-TECHNOLO..9.78%1 421
More Results

ę MarketScreener.com 2023

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2022 547 M 588 M 588 M
Net income 2022 57,1 M 61,4 M 61,4 M
Net cash 2022 62,4 M 67,1 M 67,1 M
P/E ratio 2022 18,0x
Yield 2022 0,85%
Capitalization 1 010 M 1 087 M 1 087 M
EV / Sales 2022 1,73x
EV / Sales 2023 1,57x
Nbr of Employees 2 621
Free-Float 32,7%
Upcoming event on VETOQUINOL SA
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 85,40 €
Average target price 107,55 €
Spread / Average Target 25,9%
EPS Revisions
Managers and Directors
Matthieu Jean Frechin Chief Executive Officer & Non-Independent Director
RÚgis Vimal du Monteil Chief Financial Officer
╔tienne Frechin Chairman
Sandrine Perrier Chief Information Officer
Philippe Gruet Chief Scientific Officer
MarketScreener: Created by Investors for Investors!
100% Free Registration
fermer